Compare Sumber Sinergi Makmur Tbk. (IOTF) vs Organon Pharma Indonesia Tbk. (SCPI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sumber Sinergi Makmur Tbk. vs Organon Pharma Indonesia Tbk. — how do they compare? Sumber Sinergi Makmur Tbk. trades at Rp62 (market cap 338.58B, 17.89M 24h volume), while Organon Pharma Indonesia Tbk. trades at Rp29,000 (market cap 104.4B). The key difference: Sumber Sinergi Makmur Tbk. is far larger — about 3.2× Organon Pharma Indonesia Tbk.'s market cap. Which is the better fit depends on your goals.
| IOTF | SCPI | |
|---|---|---|
Market Cap | 338.58B | 104.4B |
Volume | 17.89M | — |
Lot | 178.94K | — |
Turnover | 1.13B | — |
Average Price | 62.89 | — |
Value | 1.13B | — |
Indicative Equilibrium Price | 62 | — |
Indicative Equilibrium Volume | 15.21K | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Sumber Sinergi Makmur Tbk.
PT Sumber Sinergi Makmur Tbk (the Company) was established based on Deed Number 88 dated May 19, 2015 of H. Zainuddin, S.H., a notary domiciled in Jakarta. The company started its commercial activities in 2015. The controlling party of the Company and the party who is the ultimate beneficial owner of the Company is Alamsyah.
Read more on IOTF →About Organon Pharma Indonesia Tbk.
PT Merck Sharp Dohme Pharma Tbk was established within the frame work of the Foreign Capital Investment Law No. 1 year 1967 as amended by Law No. 11 year 1970 based on Notarial Deed No. 17 dated 7 March 1972 of Djojo Muljadi, S.H. The company originally incorporated as PT. Essex Indonesia, as a joint venture between Schering Corporation, a worldwide, research-based pharmaceutical enterprise headquartered in the United States, and an Indonesian businessman.
Read more on SCPI →
